Caveolin-1 Expression in Upper Tract Urothelial Carcinoma

David D'Andrea, Marco Moschini, Beat Foerster, Mohammad Abufaraj, Vitaly Margulis, Jose Karam, Yair Lotan, Jay Raman, Romain Mathieu, Morgan Rouprêt, Pierre I. Karakiewicz, Alberto Briganti, Andrea Haitel, Sharhrokh F. Shariat

Research output: Contribution to journalArticle

Abstract

Caveolin-1 is associated with worse oncological features among patients treated with radical nephroureterectomy for upper tract urothelial carcinoma (UTUC), but is not independently associated with oncological outcomes. Its clinical use could be explored in UTUC biopsy specimens for improving clinical staging and helping in decision-making regarding a kidney-sparing approach or neoadjuvant systemic treatment.

Original languageEnglish (US)
Pages (from-to)97-103
Number of pages7
JournalEuropean Urology Focus
Volume5
Issue number1
DOIs
StatePublished - Jan 2019

All Science Journal Classification (ASJC) codes

  • Urology

Fingerprint Dive into the research topics of 'Caveolin-1 Expression in Upper Tract Urothelial Carcinoma'. Together they form a unique fingerprint.

  • Cite this

    D'Andrea, D., Moschini, M., Foerster, B., Abufaraj, M., Margulis, V., Karam, J., Lotan, Y., Raman, J., Mathieu, R., Rouprêt, M., Karakiewicz, P. I., Briganti, A., Haitel, A., & Shariat, S. F. (2019). Caveolin-1 Expression in Upper Tract Urothelial Carcinoma. European Urology Focus, 5(1), 97-103. https://doi.org/10.1016/j.euf.2017.06.011